Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium in Relapsed/Refractory CLL/SLL
NCT00100711Phase 2Terminated
- Sponsor
- Pharmacyclics
- Start
- Oct 2004
- Primary completion
- Feb 2010
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of motexafin gadolinium in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Pharmacyclics. Started Oct 2004; status: terminated.
02
Drugs
motexafin gadolinium
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00100711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100711.